ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,505.00
      -0.71%
      US Tech 100
      19,000.00
      -0.94%
      Dow Jones
      40,287.53
      -0.93%
      Brent Oil
      81.875
      0.00%
      Bitcoin
      66,562.02
      -0.23%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Ikena Oncology Inc (IKNA) Quote

      Ikena Oncology Inc

      Ikena Oncology Inc (IKNA)

      NASDAQ
      1.66
      -0.01
      (-0.60%)
      Closed July 20 4:00PM
      Delayed by 15 minutes
      1.65
      -0.01
      (-0.60%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      1.66
      Bid
      1.62
      Ask
      1.79
      Volume
      136,418
      1.63 Day's Range 1.70
      1.02 52 Week Range 6.7953
      Market Cap
      80.591M
      Previous Close
      1.67
      Open
      1.70
      Last Trade
      1
      @
      1.65
      Last Trade Time
      Financial Volume
      $ 225,296
      VWAP
      1.6515
      Average Volume (3m)
      339,076
      Shares Outstanding
      48,258,111
      Dividend Yield
      -
      PE Ratio
      -1.17
      Earnings Per Share (EPS)
      -1.41
      Revenue
      9.16M
      Net Profit
      -68.17M

      About Ikena Oncology Inc

      Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD... Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its lead targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.ikenaoncology.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Ikena Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IKNA. The last closing price for Ikena Oncology was $1.67. Over the last year, Ikena Oncology shares have traded in a share price range of $ 1.02 to $ 6.7953.

      Ikena Oncology currently has 48,258,111 shares outstanding. The market capitalization of Ikena Oncology is $80.59 million. Ikena Oncology has a price to earnings ratio (PE ratio) of -1.17.

      IKNA Latest News

      More News

      Form 8-K - Current report

      July 12 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      June 10 2024
      Edgar (US Regulatory)

      UPDATE – Ikena Oncology Announces Strategic Update

      Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...

      May 28 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      May 28 2024
      Edgar (US Regulatory)

      Ikena Oncology Announces Strategic Update

      Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million;...

      May 28 2024
      GlobeNewswire Inc.

      Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

      Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and...

      May 13 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      May 13 2024
      Edgar (US Regulatory)

      Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

      BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today...

      April 10 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.03-1.775147928991.691.77941.631096551.70273503CS
      4-0.02-1.190476190481.681.781.63403911.66153538CS
      120.3627.69230769231.31.881.283390761.60281792CS
      26-0.04-2.352941176471.71.881.223782361.4948764CS
      52-4.49-73.00813008136.156.79531.022633661.83426053CS
      156-10.93-86.814932486112.5917.61.021764774.54096469CS
      260-20.74-92.589285714322.437.611.021779866.0851673CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      SERVServe Robotics Inc
      $ 7.51
      (185.55%)
      		266.26M
      AUGXAugmedix Inc
      $ 2.27
      (147.71%)
      		24.14M
      XCURExicure Inc
      $ 0.5351
      (76.02%)
      		14.02M
      PSNLPersonalis Inc
      $ 3.83
      (56.33%)
      		22.8M
      MDBHMDB Capital Holdings LLC
      $ 10.675
      (37.21%)
      		126.45k
      SPWRSunPower Corporation
      $ 0.6735
      (-55.40%)
      		124.61M
      HYZNHyzon Motors Inc
      $ 0.149
      (-47.54%)
      		23.63M
      MEDSTRxADE Health Inc
      $ 14.92
      (-33.45%)
      		223.27k
      SILOSilo Pharma Inc
      $ 2.50
      (-27.95%)
      		11.93M
      KITTNauticus Robotics Inc
      $ 0.0935
      (-27.46%)
      		28.43M
      SERVServe Robotics Inc
      $ 7.51
      (185.55%)
      		266.26M
      SXTP60 Degrees Pharmaceuticals Inc
      $ 0.2602
      (5.77%)
      		226.82M
      NVDANVIDIA Corporation
      $ 117.93
      (-2.61%)
      		217.11M
      SQQQProShares UltraPro Short QQQ
      $ 8.46
      (2.79%)
      		188.2M
      SPWRSunPower Corporation
      $ 0.6735
      (-55.40%)
      		124.61M

      IKNA Discussion

      View Posts
      Monksdream Monksdream 2 weeks ago
      IKNA under $2
      👍️0
      glenn1919 glenn1919 2 months ago
      IKNA.....................................https://stockcharts.com/h-sc/ui?s=IKNA&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 4 months ago
      IKNA under $2=
      👍️0
      Monksdream Monksdream 5 months ago
      IKNA under $2
      👍️0
      herbied47 herbied47 8 months ago
      $196.9M in cash, cash equivalents, and marketable securities, which it said would support operations well into 2026. $5.40 a share in cash
      Market cap 37 million as of now. Price targets still between $8 and $11. Lots of upcoming catalyst Bullish
      👍️0
      herbied47 herbied47 8 months ago
      Way over sold! https://finance.yahoo.com/news/broker-revenue-forecasts-ikena-oncology-100336585.html
      👍️0
      Tacostocks Tacostocks 8 months ago
      It went down, because it didnt have the backing of Money hunt...
      👍️0
      Money hunt Money hunt 8 months ago
      what happened here my short friend
      👍️0
      Tacostocks Tacostocks 8 months ago
      Aged like milk eh
      👍️0
      AJ Freely AJ Freely 11 months ago
      $IKNA - 👆Up 5.2% Pre-Market/ Current Price $5
      To Acquire & Merge w/ Pionyr Immunotherapeutics
      👍️0
      Tartiaboy Tartiaboy 1 year ago
      This is a very inactive board, but IKNA is worth keeping an eye on. I currently do not own any but am interested enough to follow it. Right now my biggest interest is in IKNA's new molecule IK-595- the RAF:MEK clamp. They intend to file and IND application in 2H2023. I see very big future potential for IK-595 and want to see how IKNA develops it's early clinical plan.

      I am not too familiar with there lead drug so I am neutral regarding it.
      👍️0
      TrendTrade2016 TrendTrade2016 2 years ago
      IKNA look at this beast
      👍️0
      TrendTrade2016 TrendTrade2016 2 years ago
      IKNA monster
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. It intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The Company is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. It also has early stage discovery programs in targeted oncology in the RAS pathway.
      👍️0

      Your Recent History

      NASDAQ
      IKNA
      Ikena Oncology
      ASX
      IGO
      IGO
      LBNK
      SHIKUSDT
      SHIKOKU INU
      BIT
      BRES1
      SG ETC Daily Short-1x Br...
      BIT
      UB5M25
      Unicredit Bank
      LSE
      IUKP
      Ishr Uk Prop
      Delayed Upgrade Clock